Update on rational targeted therapy in AML
详细信息 查看全文
- 作者：Danielle Shafer ; dashafer@vcu.edu" class="auth_mail" title="E-mail the corresponding author ; Steven Grant
- 关键词：High-risk AML ; IDH ; BET ; HDAC inhibitors ; LSD1 ; DOT1L ; Flavopiridol ; Palbociclib ; Volasertib ; Wee1 ; Idasanutlin ; Aurora kinase ; Rigosertib ; Hedgehog ; BH3-mimetic ; Venetoclax ; Pevonedistat ; Tosedostat
- 刊名：Blood Reviews
- 出版年：2016
- 出版时间：July 2016
- 年：2016
- 卷：30
- 期：4
- 页码：275-283
- 全文大小：344 K
文摘
Acute myeloid leukemia (AML) remains a challenge to both patients and clinicians. Despite improvements in our understanding of the disease, treatment has changed minimally and outcomes remain poor for the majority of patients. Within the last decade, there have been an increasing number of potential targets and pathways identified for development in AML. The classes of agents described in this review include but are not limited to epigenetic modifiers such as IDH inhibitors, BET inhibitors, and HDAC inhibitors as well as cell cycle and signaling inhibitors such as Aurora kinase inhibitors and CDK inhibitors. While the developments are encouraging, it is unlikely that targeting a single pathway will result in long-term disease control. Accordingly, we will also highlight potential rational partners for the novel agents described herein.